This study funded by IFF is focused on identifying new therapeutic targets to treat Pediatric Low-Grade Gliomas (PLGGs). Children diagnosed with PLGGs face a chronic illness, characterized by multiple episodes of tumor recurrence. Although children with PLGGs are likely to be long-term survivors, many are burdened with devastating life-long morbidities from their tumor and treatments.
Dana Farber’s recent findings that many PLGGs are associated with fusions of the MYB and QKI genes hold great significance as it identifies a recurrent driver alteration for the first time in angiocentric gliomas and other diffuse gliomas. Uncovering the mechanisms by which this contributes to tumor formation will allow researchers to develop genetically defined models and determine therapeutic strategies that can be translated quickly into the clinic. This could lead to targeted therapies that can improve their outcomes and quality of life.
More on Dana Farber / Boston Children’s Cancer and Blood Disorders Center here: Brain Tumor – Pediatric Cancer Treatment – Dana-Farber Cancer Institute | Boston, MA